Treatment of non-mestastatic castration resistant prostate cancer in 2020: What is the best?

被引：24
作者：
Heidegger, Isabel [1 ]
Brandt, Maximilian P. [1 ,2 ]
Heck, Matthias M. [3 ]
机构：
[1] Med Univ Innsbruck, Dept Urol, Innsbruck, Austria
[2] Mainz Univ Med, Dept Urol & Pediat Urol, Mainz, Germany
[3] Tech Univ Munich, Dept Urol, Munich, Germany
来源：
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2020年 / 38卷 / 04期
关键词：
Nonmetastatic castration-resistant prostate cancer; Enzalutamide; Apalutamide; Darolutamide; Adverse events; PSMA-PET; METASTASIS-FREE SURVIVAL; CLINICAL-TRIALS; ENZALUTAMIDE; ANTIANDROGEN; THERAPY; RECOMMENDATIONS; BICALUTAMIDE; ANTIGEN; DESIGN; PET/CT;
D O I：
10.1016/j.urolonc.2019.11.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Lately the development of 3 novel second-generation androgen receptor antagonists (enzalutamide, apalutamide, and darolutamide) chanced the treatment landscape of nonmetastatic castration-resistant prostate cancer. After proofing their clinical efficacy in large phase III registration trials with good compatibilities and tolerable side effects currently all 3 substances are Food and Drug Administration-approved in nonmetastatic castration-resistant prostate cancer. The present short review article provides an overview about these new treatment options and discusses their use in daily routine focusing on patient selection as well as on the impact of novel sensitive imaging modalities like prostate-specific membrane antigen-positron-emission tomography for detection of this stage of disease. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码：129 / 136
页数：8
相关论文
共 36 条
  • [1] Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies
    Alpajaro, Sigfred Ian R.
    Harris, Jerad A. K.
    Evans, Christopher P.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2019, 22 (01) : 16 - 23
  • [2] Metastasis-free Survival - A New End Point in Prostate Cancer Trials
    Beaver, Julia A.
    Kluetz, Paul G.
    Pazdur, Richard
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (26) : 2458 - 2460
  • [3] Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
  • [4] Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)
    Borgmann, Hendrik
    Lallous, Nada
    Ozistanbullu, Deniz
    Beraldi, Eliana
    Paul, Naman
    Dalal, Kush
    Fazli, Ladan
    Haferkamp, Axel
    Lejeune, Pascale
    Cherkasov, Artem
    Gleave, Martin E.
    [J]. EUROPEAN UROLOGY, 2018, 73 (01) : 4 - 8
  • [5] ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
    Clegg, Nicola J.
    Wongvipat, John
    Joseph, James D.
    Tran, Chris
    Ouk, Samedy
    Dilhas, Anna
    Chen, Yu
    Grillot, Kate
    Bischoff, Eric D.
    Cal, Ling
    Aparicio, Anna
    Dorow, Steven
    Arora, Vivek
    Shao, Gang
    Qian, Jing
    Zhao, Hong
    Yang, Guangbin
    Cao, Chunyan
    Sensintaffar, John
    Wasielewska, Teresa
    Herbert, Mark R.
    Bonnefous, Celine
    Darimont, Beatrice
    Scher, Howard I.
    Smith-Jones, Peter
    Klang, Mark
    Smith, Nicholas D.
    De Stanchina, Elisa
    Wu, Nian
    Ouerfelli, Ouathek
    Rix, Peter J.
    Heyman, Richard A.
    Jung, Michael E.
    Sawyers, Charles L.
    Hager, Jeffrey H.
    [J]. CANCER RESEARCH, 2012, 72 (06) : 1494 - 1503
  • [6] EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
    Cornford, Philip
    Bellmunt, Joaquim
    Bolla, Michel
    Briers, Erik
    De Santis, Maria
    Gross, Tobias
    Henry, Ann M.
    Joniau, Steven
    Lam, Thomas B.
    Mason, Malcolm D.
    van der Poel, Henk G.
    van der Kwast, Theo H.
    Rouviere, Olivier
    Wiegel, Thomas
    Mottet, Nicolas
    [J]. EUROPEAN UROLOGY, 2017, 71 (04) : 630 - 642
  • [7] The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer
    El-Amm, Joelle
    Aragon-Ching, Jeanny B.
    [J]. CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2019, 13
  • [8] Fendler WP, 2019, CLIN CANC RES
  • [9] Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
    Fizazi, Karim
    Shore, Neal
    Tammela, Teuvo L.
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris
    Kuss, Iris
    Kappeler, Christian
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (13) : 1235 - 1246
  • [10] Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
    Gillessen, Silke
    Attard, Gerhardt
    Beer, Tomasz M.
    Beltran, Himisha
    Bossi, Alberto
    Bristow, Rob
    Carver, Brett
    Castellano, Daniel
    Chung, Byung Ha
    Clarke, Noel
    Daugaard, Gedske
    Davis, Ian D.
    de Bono, Johann
    dos Reis, Rodolfo Borges
    Drake, Charles G.
    Eeles, Ros
    Efstathiou, Eleni
    Evans, Christopher P.
    Fanti, Stefano
    Feng, Felix
    Fizazi, Karim
    Frydenberg, Mark
    Gleave, Martin
    Halabi, Susan
    Heidenreich, Axel
    Higano, Celestia S.
    James, Nicolas
    Kantoff, Philip
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Khauli, Raja B.
    Kramer, Gero
    Logothetis, Chris
    Maluf, Fernando
    Morgans, Alicia K.
    Morris, Michael J.
    Mottet, Nicolas
    Murthy, Vedang
    Oh, William
    Ost, Piet
    Padhani, Anwar R.
    Parker, Chris
    Pritchard, Colin C.
    Roach, Mack
    Rubin, Mark A.
    Ryan, Charles
    Saad, Fred
    Sartor, Oliver
    Scher, Howard
    Sella, Avishay
    Shore, Neal
    [J]. EUROPEAN UROLOGY, 2018, 73 (02) : 178 - 211
1234